Skip to main content
Oklahoma Functional Medicine

Under a useful load

Reading list

Bone, hormone, bowel and safety studies

I begin among the bone dimensions, where the practical tasks and uncomfortable findings can interrupt the hormone story.

Bone measurements

The bone mineral-content paper supplies the opening question: in female rats, more mineral accompanied larger bone dimensions while cortical volumetric density was unchanged. The longitudinal-growth paper adds a graded growth response in adult female rats alongside unchanged circulating measurements. I read these together because the kinds of measurement matter to the conclusion.

Hormone release and timing

The selectivity characterization used rat pituitary cells, rats and swine. The pharmacokinetic and pharmacodynamic study moved to healthy male volunteers receiving intravenous infusions. The animal hormone profile and the human timing result each deserve the population and experimental setting that produced them.

Eating, weight and adverse findings

The rat ileus study provides the prokinetic rationale; the randomized bowel-resection trial supplies the unsuccessful human primary endpoint. The ferret study separates weight preservation from vomiting. Those outcome pairs interrupt an overly comfortable claim about recovery.

The rat toxicology paper concerns a different ghrelin-receptor agonist. Its attribution is essential. The athletic-performance review and the gerontology review discuss human evidence and safety gaps, with the latter concentrating on aging.

  1. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats ↗
  2. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats ↗
  3. Ipamorelin, the first selective growth hormone secretagogue ↗
  4. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers ↗
  5. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus ↗
  6. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients ↗
  7. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism ↗
  8. Integrated approach to early detection of cardiovascular toxicity induced by a ghrelin receptor agonist ↗
  9. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance ↗
  10. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging ↗